Quick answer
What does tendon research on BPC-157 show? Rat Achilles studies reported improved function, biomechanics and collagen organization after transection or tendon-to-bone detachment, and cell studies reported increased fibroblast migration, survival under stress, FAK-paxillin phosphorylation and growth hormone receptor expression, without a direct proliferation effect. The work is preclinical, comes from few laboratories and is hypothesis-generating. For laboratory research use only; see the BPC-157 product page.
Tendon is a useful tissue for studying repair because it is dense, poorly vascularized and slow to remodel, so any agent that changes how fast a tendon model recovers is easy to detect and hard to explain away. BPC-157 entered the tendon literature through a group working in the rat, and a second group later moved the question into cultured tendon cells. This article walks through those studies in order: the animal models and what they measured, the cell experiments that proposed mechanisms, and the limits of the evidence. It is a reading of published preclinical work for people who handle the research peptide in the laboratory; the material is for laboratory research use only and nothing here describes use in people.
Why tendon models are used
A healthy tendon is mostly type I collagen arranged in parallel fibers with sparse cells and limited blood supply. After a transection or a detachment from bone, healing proceeds through inflammation, fibroblast infiltration, collagen deposition and remodeling, and each stage can be scored. Functional scoring in rodents (such as the Achilles functional index), mechanical testing of the healed tissue and histology of collagen organization give three independent views of the same outcome, which is why tendon is attractive to groups testing a candidate peptide. The review by Gwyer and colleagues (2019) frames BPC-157 specifically as a candidate for hypovascular and hypocellular soft tissues such as tendon and ligament, and notes that growth-factor approaches have been limited by instability and carrier requirements.
For the compound background, see the BPC-157 research overview and the comparison with another tissue-repair peptide in BPC-157 vs TB-500.
The rat Achilles tendon studies
In the first major tendon paper (Staresinic et al., 2003), the right Achilles tendon of rats was transected 5 mm proximal to its calcaneal insertion, leaving a large gap between the cut ends. BPC-157, dissolved in saline with no carrier, was given intraperitoneally once daily from 30 minutes after surgery at three amounts, with saline controls. Over days 1 to 14 the authors reported improvements in the peptide groups across several readouts: biomechanically, higher load to failure, load to failure per area and Young’s modulus; functionally, higher Achilles functional index values; microscopically, more mononuclear cells and fewer granulocytes with better formation of fibroblasts, reticulin and collagen; and macroscopically, a smaller tendon defect. In cultured tendocytes, the same paper reported that the peptide had no effect on growth by itself but opposed the growth-inhibiting effect of 4-hydroxynonenal.
The follow-up study (Krivic et al., 2006) used a harder problem: the Achilles tendon was sharply detached from the calcaneal bone, a tendon-to-bone interface that does not heal spontaneously in this model. Outcomes were read between days 1 and 21. The authors reported better function, higher load to failure, stiffness and elastic modulus, better organization of collagen fibers, more type I collagen and more advanced vascular appearance in the peptide groups. A corticosteroid comparator aggravated healing in the same model, and BPC-157 was reported to reduce that aggravation.
| Model | Outcome domains reported | Key reported finding |
|---|---|---|
| Transected rat Achilles tendon (Staresinic 2003) | Function, biomechanics, histology, macroscopy | Improved recovery across domains versus saline |
| Tendon-to-bone detachment (Krivic 2006) | Function, biomechanics, collagen organization, immunohistochemistry | Improved tendon-to-bone healing; reduced corticosteroid-associated aggravation |
| Cultured tendocytes (Staresinic 2003) | Growth in culture | No growth effect alone; opposed 4-hydroxynonenal inhibition |
Cell-level studies and proposed mechanisms
The cell work asks how a peptide with no growth effect of its own could influence tissue repair. Chang and colleagues (2011) studied tendon explants and tendon fibroblasts from rat Achilles tendon. They reported that BPC-157 accelerated outgrowth of fibroblasts from explants, increased the survival of cells under hydrogen peroxide stress, increased transwell migration in a dose-dependent manner, accelerated cell spreading and induced F-actin formation, while proliferation measured by MTT assay was not directly affected. They also found dose-dependent increases in phosphorylation of FAK and paxillin, and concluded that the effects were likely mediated through the FAK-paxillin pathway, a signaling route associated with cell adhesion and migration.
A second paper (Chang et al., 2014) used cDNA microarray analysis of tendon fibroblasts exposed to the peptide and identified growth hormone receptor among the most up-regulated genes; they confirmed increased mRNA and protein expression by RT-PCR and Western blot in a dose- and time-dependent manner. When growth hormone was added to peptide-exposed cells, proliferation increased and Janus kinase 2, a downstream signaling component, was activated. The authors proposed that the peptide might potentiate the proliferative effect of growth hormone by increasing receptor expression. This is a hypothesis about sensitization rather than a demonstration that the peptide acts as a growth hormone mimetic, and it was tested in a cell system.
Vascular and cell-survival threads
Tendon repair depends on blood supply and on cell survival under stress, and two further papers touch those threads. In the Achilles detachment study the peptide group showed more advanced vascular appearance. Hsieh and colleagues (2017) separately reported pro-angiogenic activity: increased vessel density in the chick chorioallantoic membrane assay and endothelial tube formation assay, faster recovery of blood flow in the ischemic rat hind-limb muscle, and activation of a VEGFR2-Akt-eNOS signaling pathway in human vascular endothelial cells. Those experiments were not performed in tendon, so their relevance to tendon healing is an inference. Survival under oxidative stress, reported by Chang and colleagues in 2011, is a second plausible contributor, and it is the kind of effect that a laboratory can test directly with a peroxide challenge assay.
The mechanistic picture across these studies is a set of pathways, not a single receptor-ligand mechanism. The overview places those threads together; the point here is that each tendon-related claim is tied to a particular assay in a particular model.
Limits of the tendon evidence
The tendon literature has strengths and weaknesses that a careful reader should weigh. Strengths: multiple independent readouts agree in direction; the studies include comparators such as corticosteroid and saline; and the cell experiments propose testable pathways. Weaknesses are structural. Most animal data come from rats and from a small number of laboratories, which Gwyer and colleagues (2019) emphasize; the Achilles studies administered the peptide intraperitoneally from 30 minutes after injury, a design that does not model delayed or local administration; and the 2025 systematic review (Vasireddi et al.) found only one clinical study among its 36 included papers. Blinding, randomization and sample-size justification are not always described in the older papers, and publication bias toward positive results is possible in any small literature.
The practical implication is that the tendon studies are hypothesis-generating. Independent replication, with a documented lot and a defined stock, would add more to the literature than a further variation on the same model.
Designing a tendon-cell experiment with the peptide
A laboratory wishing to reproduce the cell-level observations can borrow the structure of the Chang experiments. A reasonable design uses primary tendon fibroblasts or a documented line, a concentration series with a vehicle control matched to the diluent, a scrambled-sequence peptide, and a pathway readout such as phospho-FAK and phospho-paxillin by Western blot, a migration assay in transwells, and a survival assay under a defined oxidative challenge. Each arm should be run in independent biological replicates with the same lot and the same thaw history.
| Question | Assay | Control to include |
|---|---|---|
| Does the peptide affect migration? | Transwell filter migration, wound closure | Vehicle, scrambled peptide |
| Does it affect survival under stress? | Hydrogen peroxide challenge with viability readout | Vehicle, antioxidant positive control |
| Does it activate adhesion signaling? | Phospho-FAK and phospho-paxillin blots | Total protein loading control, inhibitor arm |
| Does it alter receptor expression? | RT-PCR and Western blot for growth hormone receptor | Time-matched untreated cells |
| Does it affect proliferation? | MTT or direct cell counts | Serum-containing and serum-free conditions |
Reproducibility depends on the stock as much as on the assay. Prepare it from a documented lot with a defined method (how to reconstitute a lyophilized peptide), make concentrations from the formula c = m ÷ V with the reconstitution calculator, and file the lot’s certificate from the COA library where one is published. Storage reasoning is in storing research peptides. For the regulatory framing of such materials see what are research peptides.
Frequently asked questions
What did the rat Achilles tendon studies measure?
Function (Achilles functional index), biomechanics (load to failure, stiffness, elastic modulus), histology and immunohistochemistry of collagen, and macroscopic defect size, over 14 to 21 days after surgery.
What was the difference between the 2003 and 2006 tendon studies?
The 2003 study used a transected Achilles tendon with a gap between the ends; the 2006 study used detachment of the tendon from bone, a tendon-to-bone interface that does not heal spontaneously in this model, and added a corticosteroid comparator.
Did BPC-157 increase tendon fibroblast proliferation in culture?
The 2011 study reported no direct effect on proliferation by MTT assay. It reported increased explant outgrowth, survival under peroxide stress, migration and spreading.
What signaling pathway was proposed for the migration effect?
The 2011 authors reported dose-dependent increases in phosphorylation of FAK and paxillin and proposed that the effects were likely mediated through the FAK-paxillin pathway.
What was the growth hormone receptor finding?
A 2014 study found growth hormone receptor among the most up-regulated genes in tendon fibroblasts exposed to the peptide, and reported that growth hormone then increased proliferation and activated JAK2 in those cells.
Are the tendon results from independent laboratories?
The main animal studies come from a small number of groups, and a 2019 review emphasizes that only a handful of groups have performed in-depth studies. Independent replication would strengthen the evidence.
Do the tendon studies prove an effect in people?
No. They are preclinical studies, mostly in rats, and a 2025 systematic review found only one clinical study among 36 included papers.
How is a tendon-cell experiment with BPC-157 controlled?
Include a vehicle control matched to the diluent, a scrambled-sequence peptide, a pathway positive control and a time-matched untreated arm, with independent replicates from the same lot.
Why was a corticosteroid used in the detachment study?
As a comparator that impairs tendon healing in the model. The authors reported that the corticosteroid aggravated healing and that the peptide reduced that aggravation.
Where can I find the lot documentation for the peptide?
The COA library lists certificates where they have been published, and the product page lists purity and storage information. All material is for laboratory research use only.
Related reading: BPC-157 Gastrointestinal Animal Research: A Model Map, BPC-157 Mechanism of Action: Proposed Pathways Reviewed, BPC-157 and TB-500 Storage and Stability Compared.
References
- Staresinic M, Petrovic I, Novinscak T, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. doi:10.1016/S0736-0266(03)00110-4
- Krivic A, Majerovic M, Jelic I, Seiwerth S, Sikiric P. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res. 2006;24(5):982-989. doi:10.1002/jor.20096
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010
- Chang CH, Tsai WC, Hsu YH, Pang JHS. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules. 2014;19(11):19066-19077. doi:10.3390/molecules191119066
- Hsieh MJ, Lee CH, Chueh HY, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323-333. doi:10.1007/s00109-016-1488-y
- Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019;377(2):153-159. doi:10.1007/s00441-019-03016-8
- Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485-495. doi:10.1177/15563316251355551
